Introduction
Gaucher disease type 1 (GD1) is an inherited lysosomal storage disorder characterized by deficient activity of the enzyme acid β-glucosidase [1] . As a result, glucosylceramide accumulates primarily in lysosomes of tissue macrophages leading to multisystem manifestations, including hepatosplenomegaly, anemia, thrombocytopenia, and bone disease [1, 2] .
Two treatment approaches have been used in GD1 to restore the balance between glucosylceramide synthesis and degradation. Enzyme replacement therapy (ERT) with recombinant acid β-glucosidase, the standard of care for more than two decades, augments the patient's residual enzyme activity to break down accumulated glucosylceramide and can improve or reverse hematologic, visceral, and skeletal manifestations [3] [4] [5] . Substrate reduction therapy (SRT) inhibits glucosylceramide synthase, thereby slowing production of the substrate glucosylceramide and decreasing its accumulation [6] . Eliglustat (Cerdelga®, Sanofi Genzyme, Cambridge, MA, USA) [6] is an oral SRT recently approved by the United States (US) Food and Drug Administration and the European Medicines Agency as a first-line treatment for adults with GD1 who are CYP2D6 extensive, intermediate, or poor metabolizers (N90% of patients [7] ). Clinical trials demonstrated that eliglustat reduces spleen and liver volumes and increases hemoglobin levels and platelet counts in treatment-naïve adults with GD1 [8, 9] and maintains stability long-term [10, 14] . The relevant comparison of treatment-naïve GD1 patients treated with eliglustat (SRT) and imiglucerase (ERT) has not been studied. A head-to-head trial comparing eliglustat to ERT in treatment-naïve patients is not feasible due to the difficulty of enrolling the large number of patients such a trial would require, given the rarity and heterogeneity of GD and the availability of effective intravenous treatments. The posthoc analysis we describe compares clinical response to eliglustat in treatment-naïve patients in the eliglustat clinical trials with clinical response to imiglucerase in selected treatment-naïve patients from an observational database. This evaluation was prepared for European regulatory authorities during their assessment of eliglustat, given that a clinical trial comparing eliglustat to imiglucerase in treatment-naïve patients was not feasible.
Materials and methods
We performed a post-hoc analysis of treatment-naïve patients comparing the results of eliglustat treatment in two clinical studies (12- 
Contents lists available at ScienceDirect
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Inclusion and exclusion criteria from the two eliglustat clinical studies [8, 9] were used to select a similar population of imiglucerase-treated patients from the Registry for comparison of organ volume, hematologic, and skeletal outcomes with eliglustat-treated patients. These criteria included known date of GD1 diagnosis; imiglucerase treatment initiation at age 16-65 years; no splenectomy; baseline hemoglobin 8-16 g/dL, platelet count 30-120 × 10 Among the evaluated Registry cohort of patients, sufficient data on bone (i.e., bone mineral density, bone pain, and bone crises) were not available; therefore, bone disease parameters were excluded from this analysis.
Results and discussion
The study population consisted of 46 eliglustat-treated patients (26 from Phase 2, 20 from Phase 3 ENGAGE) and 75 imiglucerase-treated Registry patients who met the inclusion criteria and had an imiglucerase dose ≥ 15 U/kg/2 weeks (mean: 35, range: 15-60). The three groups were similar with respect to percent male (38-49%), mean age at diagnosis (22-25 years), and mean age at first treatment (32-35 years). Registry data were mostly complete through 12 months (n = 64/71 for organ volumes, n = 71/75 for hematologic parameters).
Eliglustat-treated and imiglucerase-treated patients were comparable on baseline hematologic parameters; baseline spleen and liver volumes were higher in the eliglustat Phase 2 study patients than in the ENGAGE and Registry patients (Fig. 1) . Mean spleen and liver volumes decreased from baseline with eliglustat treatment, with time courses and degrees of improvement similar to the imiglucerase-treated patients from the Registry (Fig. 1A and 1B) . The rate and extent of increase Fig. 1 . Change from baseline in organ volumes and hematologic parameters. for platelet counts and hemoglobin level were similar across the eliglustat-treated and imiglucerase-treated cohorts (Fig. 1C and 1D) .
Limitations of this analysis include the post-hoc design and comparison of eliglustat-treated patients in clinical studies with imiglucerasetreated patients in a real-world setting. Although the imiglucerasetreated patients met the same inclusion and exclusion criteria as the patients in the Phase 2 and Phase 3 ENGAGE studies, baseline spleen and liver volumes differed across the cohorts, and bone data for the Registry patients were too limited to allow for a meaningful comparison. Furthermore, because adverse event data are not recorded in the ICGG Registry, it is not possible to make comparisons or draw conclusions about the safety of eliglustat versus imiglucerase. We could not completely control for baseline characteristics or for imiglucerase dose, both of which can influence treatment response. With regard to eliglustat dosing, the dose-titration scheme utilized in the clinical trials to ensure plasma eliglustat steady-state pre-dose concentrations above 5 ng/mL differs from the approved eliglustat dosing in the US and European product labels, which is determined by the patient's CYP2D6 metabolizer phenotype (i.e., extensive, intermediate, or poor metabolizer). Pharmacokinetic analyses from the clinical trials showed that pre-dose concentrations N5 ng/mL were not required for therapeutic efficacy and that CYP2D6 phenotype was the most significant determinant of eliglustat exposure.
Conclusions
Although lacking the rigor of a head-to-head trial, the findings of this post-hoc analysis in treatment-naïve GD1 patients suggest that, during the initial 9-12 months of treatment, oral eliglustat therapy results in improved organ volumes and hematologic parameters that are comparable to those observed with imiglucerase infusions.
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